BLA

Stock exchange concept
Biotech

Omeros stock up after data analysis spurs BLA resubmission plan

Given the results, Omeros hopes the anti-MASP-2 antibody narsoplimab will become the first treatment on the market in the indication.
Gabrielle Masson Dec 19, 2024 10:54am
Biogen biologics plant in Denmark

Biogen tests FDA with controversial aducanumab filing

Jul 8, 2020 10:55am
Breast Cancer Cells

Troubled Immunomedics tries again at FDA after rejection

Dec 5, 2019 7:20am